Press release
Herpes Zoster Therapeutics Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight
Discover Key Insights into the Herpes Zoster Market with DelveInsight's In-Depth Report @ Herpes Zoster Market Size [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Herpes Zoster Market Report
* In November 2024:- Sanofi Pasteur, a Sanofi Company- To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4).
* According to analysis, approximately one in every three individuals residing in the United States will experience an episode of shingles, medically referred to as herpes zoster, during their lifetime. It is estimated that around one million individuals are affected by shingles annually within the country.
* Based on our secondary analysis, in Japan the herpes zoster prevalence among individuals in the general population aged 50 years and above is approximately 10 per 1000 person-years (PY), with a higher prevalence observed among those aged 60 years and above. Moreover, the incidence escalates to more than 12 per 1000 PY in individuals aged 80 years and older.
* Among the 7MM, the lowest number of healthy patient population at-risk for herpes zoster was found to be in Spain.
* Assessments showed that among the European countries, Germany had the highest eligible patient population for herpes zoster vaccination and and are expected to increase by 2034.
* Elderly individuals and those with weakened immune systems, considered high-risk groups, may encounter cumulative incidences of up to 50%.
* The leading Herpes Zoster Companies such as Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc, Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany Biosciences, EMS, Nobelpharma, Bristol-Myers Squibb , and others.
* Promising Herpes Zoster Therapies such as JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine , and others
Stay ahead in the Herpes Zoster Therapeutics Market with DelveInsight's Strategic Report @ Herpes Zoster Market Outlook [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Herpes Zoster Epidemiology Segmentation in the 7MM
* Total Healthy Patient Population at-risk for Herpes Zoster
* Eligible Patient Population for Herpes Zoster Vaccination
Download the report to understand which factors are driving Herpes Zoster Epidemiology trends @ Herpes Zoster Prevalence [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marketed Herpes Zoster Therapies
* Shingrix : GlaxoSmithKline (GSK)
Shingrix (herpes zoster vaccine recombinant, adjuvant), also known as GSK1437173A is a non-live, recombinant subunit vaccine that help prevent Herpes Zoster (herpes zoster) in adults 50 years of age and older. The vaccine combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity that occurs as people age. Shingrix is given intramuscularly in two doses. Shingrix is currently licensed for use in the EU, US, Canada, Japan, China, and Australia.
Emerging Herpes Zoster Therapies
* CRV-101: Curevo Inc.
CRV-101 is an investigational adjuvanted subunit vaccine under investigation for the prevention of Herpes Zoster in older adults. CRV-101 was specifically designed to produce an optimal immune response while using a smaller amount of adjuvant with the intention of achieving similar efficacy but with fewer side effects than the currently-approved Herpes Zoster vaccine. On September 2022, Curevo announced completion of enrollment in a Phase IIb trial of their CRV-101 subunit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.
To know more about Herpes Zoster treatment guidelines, visit @ Herpes Zoster Treatment Market Landscape [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Herpes Zoster Therapies and Companies
* JCXH-105: Immorna Biotherapeutics, Inc./ICON plc
* TNM005: Zhuhai Trinomab Pharmaceutical Co., Ltd.
* CRV-101 Vaccine Antigen High Dose: Curevo Inc/Green Cross Corporation
* mRNA-1468: ModernaTX, Inc.
* PF-07915234: Pfizer
* HZ/su vaccine: GlaxoSmithKline
* Herpes Zoster Vaccine GSK1437173A: GlaxoSmithKline
* Varicella Zoster Vaccine: Bristol-Myers Squibb
Herpes Zoster Market Dynamics
The herpes zoster market dynamics have undergone significant changes over the years. Firstly, the aging population is a significant driver. As the global population continues to age, the risk of developing herpes zoster increases, creating a growing patient pool for antiviral medications and vaccines. Additionally, advancements in medical research and development have brought new treatments and vaccines to the market. Vaccination campaigns, such as the introduction of the varicella-zoster vaccine, have helped reduce the incidence and severity of herpes zoster. This, in turn, affects the demand for antiviral medications and preventive treatments.
Learn more about the FDA-approved drugs for Herpes Zoster @ Drugs for Herpes Zoster Treatment [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Herpes Zoster Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Herpes Zoster Companies- Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others
* Herpes Zoster Therapies- JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
* Herpes Zoster Unmet Needs, KOL's views, Analyst's views, Herpes Zoster Market Access and Reimbursement
Table of Content
1. Key Insights
2. Report Introduction
3. Herpes Zoster (Shingles) Market Overview at a Glance
4. Herpes Zoster Epidemiology and Market Methodology
5. Herpes Zoster Executive Summary
6. Key Events
7. Herpes Zoster Disease Background and Overview
8. Herpes Zoster Epidemiology and Patient Population
9. Herpes Zoster Patient Journey
10. Herpes Zoster Marketed Products
11. Herpes Zoster Emerging Treatment and Management
12. Herpes Zoster: 7 Major Market Analysis
13. Herpes Zoster SWOT Analysis
14. Herpes Zoster KOL Views
15. Herpes Zoster Unmet Needs
16. Herpes Zoster Market Access and reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=herpes-zoster-therapeutics-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Zoster Therapeutics Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight here
News-ID: 3790295 • Views: …
More Releases from ABNewswire
Spinal Cord Injury Pipeline Outlook Report 2025: Tracking the Most Promising Dru …
DelveInsight's "Spinal Cord Injury Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spinal Cord Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Lupus Nephritis Pipeline Outlook Report 2025: Tracking the Most Promising Drugs …
DelveInsight's "Lupus Nephritis Pipeline Insight 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Friedreich's Ataxia Pipeline Outlook Report 2025: Tracking the Most Promising Dr …
DelveInsight's "Friedreich's Ataxia Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Friedreich's Ataxia pipeline landscape. It covers the Friedreich's Ataxia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Friedreich's Ataxia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
From Pandemic Paintings to Luxury Candles: Chere Maison Brings Art and Light to …
Family-operated Chere Maison launches with hand-painted glass candle jars created by self-taught artist Traci Mitchell, who began painting during COVID to spread positivity. The brand combines artisanal craftsmanship with charitable mission to bring joy through functional art.
The transformation of pandemic creativity into entrepreneurial success defines Chere Maison, a new luxury candle brand that emerged from artist Traci Mitchell's COVID-era journey of self-discovery and generous spirit. What began as daily painting…
More Releases for Zoster
Innovations and Growth in the Herpes Zoster Ophthalmicus Drug Market
Herpes Zoster Ophthalmicus (HZO) presents a significant clinical challenge, with the varicella-zoster virus reactivating in the ophthalmic division of the trigeminal nerve to cause painful, vision-threatening complications. Over the past decade, heightened awareness of HZO's potential to cause chronic ocular inflammation, corneal scarring, and vision loss has driven robust investment in both antiviral and adjunctive therapies. As patient populations continue to age and the prevalence of immunocompromising conditions rises globally,…
Herpes Zoster Pipeline Therapeutics Assessment 2024 (Updated)
DelveInsight's, "Herpes Zoster Pipeline Insight 2024," report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Herpes Zoster Research. Learn more…
Herpes Zoster Treatment Market Analysis and Future Prospects for 2030
The world of the herpes zoster treatment market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
Zoster Vaccine Live Market | GSK, Merck, ,
The global zoster vaccine live market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the zoster vaccine live market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Herpes Zoster Market Share, Size, Insights, Trends, and Forecast 2032
A detailed review of the historical and forecasted Herpes Zoster market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Herpes Zoster market.
Herpes Zoster: An Overview
Herpes zoster (HZ), also called Shingles, is a neurocutaneous disease that is generally caused by the reactivation of varicella-zoster virus (VZV) from a latent…
Zoster Vaccine Live Market global outlook and forecast 2021 -2027
The Global Zoster Vaccine Live Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Zoster Vaccine Live makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise…
